Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

NCT07673900 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight and/or Obesity

Interventions

COMBINATION_PRODUCT: VX-201
DRUG: semaglutide SC

Sponsor

Terrestrial Bio, Inc.

Collaborators

[object Object]